Humira

Drug Overview
Product Profiles
Humira: Crohn's disease
Humira: Axial spondyloarthritis
Humira: Rheumatoid arthritis
Humira: Psoriatic arthritis
Humira: Ulcerative colitis
Humira: Psoriasis

Figure 1: Humira for Crohn’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of Humira in Crohn’s disease
Figure 3: The authors drug assessment summary of Humira in Crohn’s disease
Figure 4: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Humira for axial spondyloarthritis – SWOT analysis
Figure 6: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 7: The authors drug assessment summary of Humira in axial spondyloarthritis
Figure 8: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 9: Humira for rheumatoid arthritis – SWOT analysis
Figure 10: The authors drug assessment summary of Humira in rheumatoid arthritis
Figure 11: The authors drug assessment summary of Humira in rheumatoid arthritis
Figure 12: Humira for psoriatic arthritis – SWOT analysis
Figure 13: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 14: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 15: Humira for ulcerative colitis – SWOT analysis
Figure 16: The authors drug assessment summary of Humira for ulcerative colitis
Figure 17: The authors drug assessment summary of Humira for ulcerative colitis
Figure 18: Humira for psoriasis – SWOT analysis
Figure 19: The authors drug assessment summary of Humira in psoriasis
Figure 20: The authors drug assessment summary of Humira in psoriasis

Table 1: Humira drug profile
Table 2: Humira pivotal trial data in adult Crohn’s disease
Table 3: Humira pivotal trial data in pediatric Crohn’s disease
Table 4: Humira ongoing trials in Crohn’s disease
Table 5: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 6: Humira drug profile
Table 7: Humira pivotal trial data in axial spondyloarthritis
Table 8: Humira late-phase trial data in axial spondyloarthritis
Table 9: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
Table 10: Humira drug profile
Table 11: Humira pivotal trial data in rheumatoid arthritis
Table 12: Humira late-phase trial data in rheumatoid arthritis
Table 13: Humira drug profile
Table 14: Humira pivotal trial data in psoriatic arthritis
Table 15: Humira late-phase trial data in psoriatic arthritis
Table 16: Humira drug profile
Table 17: Humira pivotal trial data in ulcerative colitis
Table 18: Humira ongoing late-phase trials in ulcerative colitis
Table 19: Humira drug profile
Table 20: Humira pivotal trial data in adult psoriasis
Table 21: Humira pivotal trial data in pediatric psoriasis
Table 22: Humira late-phase trial data in psoriasis
Table 23: Humira ongoing late-phase clinical trials in psoriasis